ERBB2 and cholangiocarcinoma: Importantly, a patient with advanced cholangiocarcinoma who only had mRNA results (and not genomic or IHC results) and had HER2 transcript expression showed a sustained partial response to anti-HER2 therapy ongoing at 2 years.